Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

Chronic Idiopathic Thrombocytopenic Purpura Clinical Trial

Official title:
A Safety, Pharmacokinetics and Pharmacodynamics Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura

Status Recruiting

Clinical Trial Summary

This study evaluates the safety and efficacy of 6 weeks dosing Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura Patients. All of the subjects in this study receive Hetrombopag.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Chronic Idiopathic Thrombocytopenic Purpura
Purpura
Purpura, Thrombocytopenic
Purpura, Thrombocytopenic, Idiopathic

Clinical Trial Details

NCT number	NCT02614846
Study type	Interventional
Source	Jiangsu HengRui Medicine Co., Ltd.
Contact	Yu Hu, Ph.D
Email	dr_huyu@126.com
Status	Recruiting
Phase	Phase 1
Start date	August 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00540423` - Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)	Phase 3
Completed	`NCT00504075` - A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)	Phase 3
Completed	`NCT04071496` - Diagnostic of Chronic Thrombocytopenia
Completed	`NCT00467571` - Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura	Phase 4
Completed	`NCT00441090` - Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)	Phase 2